Mitral regurgitation

Maurice E Sarano, Cary W. Akins, Alec Vahanian

Research output: Contribution to journalArticle

443 Citations (Scopus)

Abstract

Mitral regurgitation affects more than 2 million people in the USA. The main causes are classified as degenerative (with valve prolapse) and ischaemic (ie, due to consequences of coronary disease) in developed countries, or rheumatic (in developing countries). This disorder generally progresses insidiously, because the heart compensates for increasing regurgitant volume by left-atrial enlargement, causes left-ventricular overload and dysfunction, and yields poor outcome when it becomes severe. Doppler-echocardiographic methods can be used to quantify the severity of mitral regurgitation. Yearly mortality rates with medical treatment in patients aged 50 years or older are about 3% for moderate organic regurgitation and about 6% for severe organic regurgitation. Surgery is the only treatment proven to improve symptoms and prevent heart failure. Valve repair improves outcome compared with valve replacement and reduces mortality of patient with severe organic mitral regurgitation by about 70%. The best short-term and long-term results are obtained in asymptomatic patients operated on in advanced repair centres with low operative mortality (<1%) and high repair rates (≥80-90%). These results emphasise the importance of early detection and assessment of mitral regurgitation.

Original languageEnglish (US)
Pages (from-to)1382-1394
Number of pages13
JournalThe Lancet
Volume373
Issue number9672
DOIs
StatePublished - 2009

Fingerprint

Mitral Valve Insufficiency
Mortality
Prolapse
Left Ventricular Dysfunction
Developed Countries
Developing Countries
Coronary Disease
Heart Failure
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sarano, M. E., Akins, C. W., & Vahanian, A. (2009). Mitral regurgitation. The Lancet, 373(9672), 1382-1394. https://doi.org/10.1016/S0140-6736(09)60692-9

Mitral regurgitation. / Sarano, Maurice E; Akins, Cary W.; Vahanian, Alec.

In: The Lancet, Vol. 373, No. 9672, 2009, p. 1382-1394.

Research output: Contribution to journalArticle

Sarano, ME, Akins, CW & Vahanian, A 2009, 'Mitral regurgitation', The Lancet, vol. 373, no. 9672, pp. 1382-1394. https://doi.org/10.1016/S0140-6736(09)60692-9
Sarano, Maurice E ; Akins, Cary W. ; Vahanian, Alec. / Mitral regurgitation. In: The Lancet. 2009 ; Vol. 373, No. 9672. pp. 1382-1394.
@article{3316d7f046d9454abb297d761077dfeb,
title = "Mitral regurgitation",
abstract = "Mitral regurgitation affects more than 2 million people in the USA. The main causes are classified as degenerative (with valve prolapse) and ischaemic (ie, due to consequences of coronary disease) in developed countries, or rheumatic (in developing countries). This disorder generally progresses insidiously, because the heart compensates for increasing regurgitant volume by left-atrial enlargement, causes left-ventricular overload and dysfunction, and yields poor outcome when it becomes severe. Doppler-echocardiographic methods can be used to quantify the severity of mitral regurgitation. Yearly mortality rates with medical treatment in patients aged 50 years or older are about 3{\%} for moderate organic regurgitation and about 6{\%} for severe organic regurgitation. Surgery is the only treatment proven to improve symptoms and prevent heart failure. Valve repair improves outcome compared with valve replacement and reduces mortality of patient with severe organic mitral regurgitation by about 70{\%}. The best short-term and long-term results are obtained in asymptomatic patients operated on in advanced repair centres with low operative mortality (<1{\%}) and high repair rates (≥80-90{\%}). These results emphasise the importance of early detection and assessment of mitral regurgitation.",
author = "Sarano, {Maurice E} and Akins, {Cary W.} and Alec Vahanian",
year = "2009",
doi = "10.1016/S0140-6736(09)60692-9",
language = "English (US)",
volume = "373",
pages = "1382--1394",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9672",

}

TY - JOUR

T1 - Mitral regurgitation

AU - Sarano, Maurice E

AU - Akins, Cary W.

AU - Vahanian, Alec

PY - 2009

Y1 - 2009

N2 - Mitral regurgitation affects more than 2 million people in the USA. The main causes are classified as degenerative (with valve prolapse) and ischaemic (ie, due to consequences of coronary disease) in developed countries, or rheumatic (in developing countries). This disorder generally progresses insidiously, because the heart compensates for increasing regurgitant volume by left-atrial enlargement, causes left-ventricular overload and dysfunction, and yields poor outcome when it becomes severe. Doppler-echocardiographic methods can be used to quantify the severity of mitral regurgitation. Yearly mortality rates with medical treatment in patients aged 50 years or older are about 3% for moderate organic regurgitation and about 6% for severe organic regurgitation. Surgery is the only treatment proven to improve symptoms and prevent heart failure. Valve repair improves outcome compared with valve replacement and reduces mortality of patient with severe organic mitral regurgitation by about 70%. The best short-term and long-term results are obtained in asymptomatic patients operated on in advanced repair centres with low operative mortality (<1%) and high repair rates (≥80-90%). These results emphasise the importance of early detection and assessment of mitral regurgitation.

AB - Mitral regurgitation affects more than 2 million people in the USA. The main causes are classified as degenerative (with valve prolapse) and ischaemic (ie, due to consequences of coronary disease) in developed countries, or rheumatic (in developing countries). This disorder generally progresses insidiously, because the heart compensates for increasing regurgitant volume by left-atrial enlargement, causes left-ventricular overload and dysfunction, and yields poor outcome when it becomes severe. Doppler-echocardiographic methods can be used to quantify the severity of mitral regurgitation. Yearly mortality rates with medical treatment in patients aged 50 years or older are about 3% for moderate organic regurgitation and about 6% for severe organic regurgitation. Surgery is the only treatment proven to improve symptoms and prevent heart failure. Valve repair improves outcome compared with valve replacement and reduces mortality of patient with severe organic mitral regurgitation by about 70%. The best short-term and long-term results are obtained in asymptomatic patients operated on in advanced repair centres with low operative mortality (<1%) and high repair rates (≥80-90%). These results emphasise the importance of early detection and assessment of mitral regurgitation.

UR - http://www.scopus.com/inward/record.url?scp=64549102931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549102931&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)60692-9

DO - 10.1016/S0140-6736(09)60692-9

M3 - Article

C2 - 19356795

AN - SCOPUS:64549102931

VL - 373

SP - 1382

EP - 1394

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9672

ER -